Financhill
Sell
48

ARGX Quote, Financials, Valuation and Earnings

Last price:
$848.48
Seasonality move :
2.87%
Day range:
$844.75 - $858.80
52-week range:
$510.06 - $934.62
Dividend yield:
0%
P/E ratio:
43.13x
P/S ratio:
18.10x
P/B ratio:
6.40x
Volume:
250.2K
Avg. volume:
340.6K
1-year change:
34.91%
Market cap:
$52.2B
Revenue:
$2.2B
EPS (TTM):
$21.30

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARGX
argenx SE
$1.1B $4.11 87.13% 205.62% $1,010.28
AKTX
Akari Therapeutics Plc
-- -$0.11 -- -53.67% $3.53
DBVT
DBV Technologies SA
$889.9K -$0.34 -- -80.11% $40.03
EVAX
Evaxion AS
$2.5M -$0.01 -100% -99.68% $14.19
PHG
Koninklijke Philips NV
$5B $0.32 36.56% 481.67% $32.52
QURE
uniQure NV
$5.2M -$0.86 8.51% -38.17% $55.30
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARGX
argenx SE
$848.48 $1,010.28 $52.2B 43.13x $0.00 0% 18.10x
AKTX
Akari Therapeutics Plc
$0.27 $3.53 $9.6M -- $0.00 0% --
DBVT
DBV Technologies SA
$19.03 $40.03 $520.7M -- $0.00 0% --
EVAX
Evaxion AS
$4.92 $14.19 $31.1M -- $0.00 0% 3.30x
PHG
Koninklijke Philips NV
$26.98 $32.52 $25.7B 134.93x $0.97 3.59% 1.28x
QURE
uniQure NV
$25.19 $55.30 $1.6B -- $0.00 0% 86.07x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARGX
argenx SE
-- 0.059 -- 4.92x
AKTX
Akari Therapeutics Plc
8.54% -2.620 6.43% 0.16x
DBVT
DBV Technologies SA
23.24% -1.892 5.85% 1.41x
EVAX
Evaxion AS
-- 5.637 -- 2.80x
PHG
Koninklijke Philips NV
44.81% 0.542 43.45% 0.72x
QURE
uniQure NV
69.92% 0.547 14.65% 6.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARGX
argenx SE
$837.2M $203.8M 24.23% 28.06% 30.38% $312.8M
AKTX
Akari Therapeutics Plc
-- -$2.2M -82.27% -91.86% -- -$2.1M
DBVT
DBV Technologies SA
-$4.3M -$36.9M -211.46% -280.59% -- -$32.5M
EVAX
Evaxion AS
-- -$4.4M -238.97% -- -54.59% --
PHG
Koninklijke Philips NV
$2.2B $447.6M 1% 1.55% 9.61% $170.3M
QURE
uniQure NV
-$329K -$50.7M -40.98% -382.35% -1370.5% -$17.7M

argenx SE vs. Competitors

  • Which has Higher Returns ARGX or AKTX?

    Akari Therapeutics Plc has a net margin of 25.88% compared to argenx SE's net margin of --. argenx SE's return on equity of 28.06% beat Akari Therapeutics Plc's return on equity of -91.86%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    88.32% $3.74 $6.1B
    AKTX
    Akari Therapeutics Plc
    -- -$0.19 $24.8M
  • What do Analysts Say About ARGX or AKTX?

    argenx SE has a consensus price target of $1,010.28, signalling upside risk potential of 19.38%. On the other hand Akari Therapeutics Plc has an analysts' consensus of $3.53 which suggests that it could grow by 1340.41%. Given that Akari Therapeutics Plc has higher upside potential than argenx SE, analysts believe Akari Therapeutics Plc is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    15 2 0
    AKTX
    Akari Therapeutics Plc
    2 0 0
  • Is ARGX or AKTX More Risky?

    argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison Akari Therapeutics Plc has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.076%.

  • Which is a Better Dividend Stock ARGX or AKTX?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Akari Therapeutics Plc pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARGX or AKTX?

    argenx SE quarterly revenues are $948M, which are larger than Akari Therapeutics Plc quarterly revenues of --. argenx SE's net income of $245.4M is higher than Akari Therapeutics Plc's net income of -$6.4M. Notably, argenx SE's price-to-earnings ratio is 43.13x while Akari Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 18.10x versus -- for Akari Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    18.10x 43.13x $948M $245.4M
    AKTX
    Akari Therapeutics Plc
    -- -- -- -$6.4M
  • Which has Higher Returns ARGX or DBVT?

    DBV Technologies SA has a net margin of 25.88% compared to argenx SE's net margin of --. argenx SE's return on equity of 28.06% beat DBV Technologies SA's return on equity of -280.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    88.32% $3.74 $6.1B
    DBVT
    DBV Technologies SA
    -- -$1.21 $68.9M
  • What do Analysts Say About ARGX or DBVT?

    argenx SE has a consensus price target of $1,010.28, signalling upside risk potential of 19.38%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 109.38%. Given that DBV Technologies SA has higher upside potential than argenx SE, analysts believe DBV Technologies SA is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    15 2 0
    DBVT
    DBV Technologies SA
    4 0 1
  • Is ARGX or DBVT More Risky?

    argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

  • Which is a Better Dividend Stock ARGX or DBVT?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARGX or DBVT?

    argenx SE quarterly revenues are $948M, which are larger than DBV Technologies SA quarterly revenues of --. argenx SE's net income of $245.4M is higher than DBV Technologies SA's net income of -$33M. Notably, argenx SE's price-to-earnings ratio is 43.13x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 18.10x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    18.10x 43.13x $948M $245.4M
    DBVT
    DBV Technologies SA
    -- -- -- -$33M
  • Which has Higher Returns ARGX or EVAX?

    Evaxion AS has a net margin of 25.88% compared to argenx SE's net margin of -64.14%. argenx SE's return on equity of 28.06% beat Evaxion AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    88.32% $3.74 $6.1B
    EVAX
    Evaxion AS
    -- -$1.01 $74K
  • What do Analysts Say About ARGX or EVAX?

    argenx SE has a consensus price target of $1,010.28, signalling upside risk potential of 19.38%. On the other hand Evaxion AS has an analysts' consensus of $14.19 which suggests that it could grow by 188.36%. Given that Evaxion AS has higher upside potential than argenx SE, analysts believe Evaxion AS is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    15 2 0
    EVAX
    Evaxion AS
    3 0 0
  • Is ARGX or EVAX More Risky?

    argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ARGX or EVAX?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARGX or EVAX?

    argenx SE quarterly revenues are $948M, which are larger than Evaxion AS quarterly revenues of $37.5K. argenx SE's net income of $245.4M is higher than Evaxion AS's net income of -$4.9M. Notably, argenx SE's price-to-earnings ratio is 43.13x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 18.10x versus 3.30x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    18.10x 43.13x $948M $245.4M
    EVAX
    Evaxion AS
    3.30x -- $37.5K -$4.9M
  • Which has Higher Returns ARGX or PHG?

    Koninklijke Philips NV has a net margin of 25.88% compared to argenx SE's net margin of 5.53%. argenx SE's return on equity of 28.06% beat Koninklijke Philips NV's return on equity of 1.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    88.32% $3.74 $6.1B
    PHG
    Koninklijke Philips NV
    46.36% $0.22 $22.1B
  • What do Analysts Say About ARGX or PHG?

    argenx SE has a consensus price target of $1,010.28, signalling upside risk potential of 19.38%. On the other hand Koninklijke Philips NV has an analysts' consensus of $32.52 which suggests that it could grow by 20.53%. Given that Koninklijke Philips NV has higher upside potential than argenx SE, analysts believe Koninklijke Philips NV is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    15 2 0
    PHG
    Koninklijke Philips NV
    0 3 0
  • Is ARGX or PHG More Risky?

    argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison Koninklijke Philips NV has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.74%.

  • Which is a Better Dividend Stock ARGX or PHG?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Koninklijke Philips NV offers a yield of 3.59% to investors and pays a quarterly dividend of $0.97 per share. argenx SE pays -- of its earnings as a dividend. Koninklijke Philips NV pays out 0.12% of its earnings as a dividend. Koninklijke Philips NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ARGX or PHG?

    argenx SE quarterly revenues are $948M, which are smaller than Koninklijke Philips NV quarterly revenues of $5B. argenx SE's net income of $245.4M is higher than Koninklijke Philips NV's net income of $219.7M. Notably, argenx SE's price-to-earnings ratio is 43.13x while Koninklijke Philips NV's PE ratio is 134.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 18.10x versus 1.28x for Koninklijke Philips NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    18.10x 43.13x $948M $245.4M
    PHG
    Koninklijke Philips NV
    1.28x 134.93x $5B $219.7M
  • Which has Higher Returns ARGX or QURE?

    uniQure NV has a net margin of 25.88% compared to argenx SE's net margin of -2175.87%. argenx SE's return on equity of 28.06% beat uniQure NV's return on equity of -382.35%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    88.32% $3.74 $6.1B
    QURE
    uniQure NV
    -8.89% -$1.38 $760.4M
  • What do Analysts Say About ARGX or QURE?

    argenx SE has a consensus price target of $1,010.28, signalling upside risk potential of 19.38%. On the other hand uniQure NV has an analysts' consensus of $55.30 which suggests that it could grow by 119.54%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    15 2 0
    QURE
    uniQure NV
    9 2 0
  • Is ARGX or QURE More Risky?

    argenx SE has a beta of 0.366, which suggesting that the stock is 63.397% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.

  • Which is a Better Dividend Stock ARGX or QURE?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARGX or QURE?

    argenx SE quarterly revenues are $948M, which are larger than uniQure NV quarterly revenues of $3.7M. argenx SE's net income of $245.4M is higher than uniQure NV's net income of -$80.5M. Notably, argenx SE's price-to-earnings ratio is 43.13x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 18.10x versus 86.07x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    18.10x 43.13x $948M $245.4M
    QURE
    uniQure NV
    86.07x -- $3.7M -$80.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
57
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
80
TVTX alert for Dec 25

Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.

Buy
68
KOD alert for Dec 25

Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.

Buy
64
ZCSH alert for Dec 25

Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock